ca
mobil
second
messeng
nicotin
acid
adenin
dinucleotid
phosphat
naadp
regul
intracellular
traffick
event
includ
transloc
certain
envelop
virus
endolysosom
system
target
naadpevok
ca
signal
may
therefor
effect
strategi
discov
novel
antivir
well
therapeut
disord
aid
discoveri
novel
scaffold
modul
naadpevok
ca
signal
human
cell
investig
potenti
use
sea
urchin
egg
homogen
system
screen
campaign
known
pharmacolog
inhibitor
naadpevok
ca
releas
cadpror
ip
evok
ca
releas
invertebr
system
strongli
correl
inhibit
merspseudoviru
infect
human
cell
line
primari
screen
compound
yield
eighteen
hit
exhibit
inhibit
naadpevok
ca
releas
valid
pipelin
candid
yield
seven
drug
inhibit
naadpevok
ca
releas
without
deplet
acid
ca
store
human
cell
line
candid
display
similar
penetr
inhibit
sea
urchin
system
human
cell
line
extent
inhibit
naadpevok
ca
signal
correl
well
observ
inhibit
infect
middl
east
respiratori
syndrom
coronaviru
merscov
pseudoviru
experi
support
potenti
simpl
homogen
system
screen
campaign
discov
modul
naadp
cadpr
ip
depend
ca
signal
potenti
therapeut
valu
h
atpas
inhibitor
variou
lysosom
disrupt
agent
second
agent
interfer
naadp
bind
includ
member
naadp
conform
seri
identifi
virtual
screen
nucleotid
mimet
ppad
ppnd
third
agent
act
tpc
pore
blocker
includ
ca
v
channel
antagonist
diltiazem
nifedipin
u
possibl
tetrandrin
submicromolar
rang
structurallyrel
http
doi
ca
signal
origin
acid
ca
store
endosom
lysosom
regul
steadili
grow
list
cellular
development
process
one
import
endolysosom
ca
releas
pathway
activ
nicotin
acid
adenin
dinucleotid
phosphat
naadp
potent
ca
releas
second
messeng
mani
cell
tissu
naadp
mobil
intracellular
ca
store
engag
activ
member
twopor
channel
tpc
famili
see
tpc
broadli
express
ion
channel
evolutionarili
ancient
member
voltageg
ion
channel
superfamili
identif
subsequ
studi
facilit
resolut
mani
pathophysiolog
process
depend
upon
endolysosom
ca
releas
exampl
use
knockdown
knockout
approach
role
tpc
shown
viral
infect
parkinson
diseas
muscl
function
develop
lateonset
obes
suscept
nonalcohol
fatti
liver
diseas
discoveri
priorit
import
identifi
small
molecul
modul
tpcand
naadpdepend
ca
signal
pathway
research
tool
perhap
longer
term
therapeut
avenu
exampl
natur
product
tetrandrin
recent
identifi
tpc
blocker
inhibitor
naadpevok
ca
signal
improv
surviv
mice
infect
ebola
modul
naadpdepend
signal
shown
effect
eukaryot
pathogen
viral
infect
well
regul
neoangiogenesi
current
pharmacolog
tool
inhibit
naadpevok
ca
signal
compris
sever
group
first
compound
gener
perturb
mobiliz
organellar
ca
pool
eg
bafilomycin
vacuolar
deriv
final
flotilla
compound
work
mechan
inhibitori
action
rang
ten
micromolar
includ
alkyl
pyridinium
analog
ic
na
v
blocker
ic
naringenin
ic
overal
scope
identifi
improv
pharmacopeia
select
potent
modul
naadpevok
ca
releas
pathway
one
approach
execut
unbias
screen
campaign
target
naadpsensit
ca
signal
base
upon
interrog
ca
releas
respons
sea
urchin
egg
homogen
system
prepar
ca
releas
activ
naadp
cyclic
adp
ribos
cadpr
first
discov
sea
urchin
egg
homogen
system
repres
simpl
yet
robust
prepar
easili
prepar
cellfre
system
within
independ
prepar
provid
reproduc
robust
respons
multipl
ca
releas
second
messeng
naadp
cadpr
ip
within
minaturiz
high
signaltonois
room
temperatur
assay
homogen
prepar
bulk
store
frozen
aliquot
remain
respons
mani
year
reason
system
long
regard
goldstandard
studi
naadp
action
frequent
use
assess
action
molecul
elicit
ca
releas
discret
endogen
ca
mobil
pathway
although
system
clearli
amen
high
throughput
profil
screen
campaign
knowledg
yet
report
surpris
given
mani
advantag
prepar
least
intrins
sensit
three
ca
releas
second
messeng
permit
counterscreen
small
molecul
specif
perform
pilot
screen
novel
modul
naadpsensit
ca
releas
sea
urchin
egg
homogen
system
assess
tractabl
result
hit
endogen
naadpevok
ca
respons
pseudotyp
merscov
transloc
assay
human
cell
line
chemic
sourc
follow
lysotrack
red
ltr
thermo
scientif
pentapotassium
salt
biotium
gpn
santa
cruz
biotechnolog
skf
hydrochlorid
hydrochlorid
pdmp
hydrochlorid
ppad
tetrasodium
salt
cayman
chemic
fluphenazin
dihydrochlorid
dihydrochlorid
racecadotril
clemastin
fumar
prochlorperazin
dimal
salt
thioridazin
hydrochlorid
salmeterol
xinafo
oxybutynin
chlorid
trifluoperazin
dihydrochlorid
naringenin
hepe
chap
potassium
glucon
nmethylglucamin
nad
naad
nadp
nicotinamid
mononucleotid
nicotin
acid
nicotinamid
atp
dtt
sigma
aldrich
propyl
di
pfluorophenyl
methyl
ether
hydrochlorid
ipfm
hydrochlorid
santa
cruz
biotechnolog
dilazep
hydrochlorid
tocri
edtafre
proteas
inhibitor
cocktail
roch
naadp
cadpr
synthes
hous
use
previous
describ
method
librari
use
screen
activ
sourc
sigma
lopac
librari
pharmacolog
activ
compound
compound
selleck
gpcr
compound
librari
compound
lopac
librari
compound
screen
triplic
n
independ
assay
smaller
gpcr
librari
compound
screen
duplic
n
independ
assay
owe
limit
materi
strongylocentrotu
purpuratu
homogen
prepar
previous
describ
store
subsequ
usag
homogen
load
ca
incub
intracellular
medium
consist
mm
potassium
glucon
mm
nmethyldglucamin
mm
hepe
mm
mgcl
ph
supplement
mgml
creatin
kinas
mm
atp
mm
phosphocreatin
homogen
dilut
stepwis
fashion
cours
h
final
concentr
homogen
fluoresc
monitor
use
tecan
infinit
pro
plate
reader
ex
nm
em
nm
baselin
fluoresc
read
sampl
presenc
individu
drug
measur
follow
stimul
submaxim
concentr
naadp
screen
studi
perform
assay
plate
corn
flat
bottom
transpar
librari
screen
final
concentr
epmot
liquid
handl
workstat
eppendorf
use
dispens
homogen
naadp
assay
plate
fluoresc
monitor
use
tecan
infinit
pro
plate
reader
screen
experi
fluoresc
chang
monitor
presenc
compound
cycl
min
prior
addit
ec
concentr
naadp
nm
final
concentr
lopac
librari
vehicl
dmso
compound
mm
dispens
assay
plate
use
labcyt
acoust
nanolit
dispens
system
assay
start
addit
sea
urchin
egg
homogen
experi
screen
selleck
gpcr
compound
librari
baselin
fluoresc
homogen
monitor
min
prior
addit
vehicl
dmso
compound
mm
use
epmot
z
valu
calcul
assess
separ
distribut
posit
neg
control
describ
elsewher
pnaadp
bind
ca
releas
assay
sea
urchin
egg
homogen
p
naadp
synthes
p
nad
use
bind
studi
previous
describ
imag
experi
assess
chang
lysosom
properti
ca
content
human
cell
bone
osteosarcoma
seed
optic
bottom
black
wall
plate
thermo
scientif
densiti
cell
per
well
h
co
cell
load
lysotrack
red
ltr
accord
vendor
respect
protocol
cell
thoroughli
rins
media
replac
hank
balanc
salt
solut
hbss
thermo
scientif
fluoresc
ltr
ex
nm
em
nm
ex
nm
em
nm
simultan
monitor
use
tecan
infinit
pro
plate
reader
baselin
fluoresc
valu
monitor
cycl
follow
addit
either
vehicl
drug
final
concentr
chang
fluoresc
valu
monitor
addit
cycl
cell
treat
gpn
final
concentr
stimul
osmot
disrupt
lysosom
ca
releas
fluoresc
monitor
cycl
chang
lysosom
ca
content
due
drug
treatment
quantifi
assess
fluoresc
ratio
ff
gpn
treatment
control
drugtreat
sampl
f
repres
fluoresc
peak
f
repres
fluoresc
time
chang
lysosom
label
due
drug
treatment
quantifi
assess
fluoresc
ratio
ff
ltr
drug
treatment
f
repres
minimum
ltr
fluoresc
ratio
drug
addit
prior
gpn
treatment
f
repres
ltr
fluoresc
time
naadp
microinject
assay
human
cell
perform
describ
companion
paper
cell
seed
white
plate
corn
densiti
cell
per
well
follow
day
cell
cultur
supplement
test
compound
vehicl
h
co
viabil
cell
assess
use
celltiterglo
promega
accord
vendor
protocol
atpdepend
luciferas
activ
celltiterglo
reagent
quantifi
use
plate
reader
tecan
infinit
pro
mer
pseudoviru
experi
perform
cell
human
hepatocytederiv
carcinoma
describ
companion
paper
brief
merscov
spike
pseudotyp
retrovirus
express
luciferaseencod
report
gene
gener
transfect
cell
plasmid
carri
envdefect
luciferaseexpress
genom
plasmid
encod
merscov
spike
protein
follow
receptormedi
endocytosi
merspseudoviru
transloc
viral
particl
lumen
endolysosom
system
cytosplasm
detect
h
post
infect
measur
luciferas
activ
initi
feasibl
test
valid
screen
sea
urchin
egg
homogen
discov
lead
mammalian
activ
took
advantag
exist
compound
dataset
result
mer
pseudoviru
bioassay
set
compound
known
display
variou
degre
attenu
mer
pseudoviru
infect
screen
inhibit
ca
releas
sea
urchin
egg
homogen
system
typic
experi
shown
fig
resolv
ca
releas
kinet
evok
naadp
cadpr
ip
absenc
presenc
fangchinolin
fangchinolin
inhibitor
naadpevok
ca
signal
mer
pseudoviru
transloc
human
cell
line
decreas
magnitud
naadpevok
ca
releas
peak
amplitud
control
respons
blue
trace
fig
lesser
effect
size
ip
cadprevok
ca
transient
fig
ca
releas
assay
perform
ligand
shown
inhibitor
mer
pseudoviru
transloc
assay
impact
ligand
ca
signal
evok
naadp
cadprand
ip
correl
effect
viral
assay
fig
inspect
regress
plot
dataset
reveal
compound
inhibit
naadpevok
ca
releas
associ
blockad
mer
pseudoviru
transloc
effect
naadp
inhibitor
caus
greater
decreas
infect
fig
posit
correl
seen
ident
set
compound
modul
either
cadpr
ip
evok
signal
mer
pseudoviru
transloc
fig
overal
data
establish
identif
pharmacolog
inhibitor
naadpevok
ca
signal
sea
urchin
system
potenti
util
discov
modul
naadp
depend
process
human
cell
mer
pseudoviru
transloc
provid
rational
broader
screen
campaign
sea
urchin
egg
homogen
discov
novel
modul
naadpevok
ca
releas
schemat
overview
fourstep
screen
workflow
shown
fig
primari
screen
fix
concentr
compound
secondari
valid
potenti
hit
full
concentr
respons
curv
analysi
perform
use
sea
urchin
egg
homogen
step
miniatur
format
plate
activ
would
predict
yield
smaller
number
candid
subsequ
labori
valid
approach
human
cell
line
final
activ
step
encompass
counterscreen
gener
action
acid
ca
store
exampl
lysosomotrop
ii
quantifi
effect
naadpevok
ca
signal
evok
singl
cell
microinject
naadp
iii
correl
effect
ca
releas
bioactiv
mer
pseudoviru
transloc
assay
express
mean
sem
b
correl
plot
compar
extent
inhibit
naadp
blue
ip
red
cadprevok
ca
releas
green
observ
individu
ligand
correl
extent
inhibit
merspseudoviru
transloc
evok
ligand
concentr
none
test
ligand
evok
ca
releas
solid
naadp
dot
line
ip
cadpr
repres
linear
regress
datapoint
ligand
key
dmso
tubocurarin
merspseudoviru
infect
measur
use
luciferasebas
cell
entri
assay
assay
methodolog
inhibit
naadpevok
ca
shown
figur
describ
detail
companion
paper
overal
pipelin
would
therefor
evalu
translat
compound
discov
urchin
screen
platform
modul
naadpevok
ca
signal
mammalian
cell
first
optim
condit
execut
miniatur
screen
sea
urchin
egg
homogen
defin
basic
protocol
depict
fig
compound
preincub
homogen
min
addit
fluoresc
read
monitor
follow
singl
subsequ
addit
naadp
nm
addit
posit
control
naadp
addit
fig
known
selfdesensit
sea
urchin
naadpevok
ca
releas
pathway
neg
control
dual
addit
vehicl
fig
posit
naadp
neg
vehicl
dmso
control
run
parallel
plate
robust
screen
platform
assess
calcul
z
factor
z
wide
employ
indic
assay
qualiti
screen
applic
z
valu
consid
prerequisit
execut
reliabl
higher
throughput
screen
calcul
z
therefor
made
use
peak
fluoresc
valu
naadpevok
ca
mobil
respons
initi
preincub
vehicl
control
versu
dual
vehicl
addit
fig
averag
replic
well
within
well
plate
use
protocol
z
accept
valu
defin
assay
condit
subsequ
experi
primari
screen
compound
perform
use
two
librari
lopac
compound
g
protein
coupl
receptor
gpcr
librari
compound
result
dual
librari
screen
present
togeth
fig
collat
averag
magnitud
naadpevok
ca
signal
observ
follow
preincub
compound
data
replot
fig
progress
rank
inhibit
penetr
inhibitor
compound
show
potenti
versu
control
naadp
signal
phenytoin
compound
screen
fell
within
rang
control
valu
shade
area
fig
reassuringli
two
establish
inhibitor
naadpevok
ca
releas
pnaadp
bind
sea
urchin
egg
homogen
systemth
purinerg
blocker
ppad
ppnd
display
clear
inhibitori
effect
primari
screen
naadpevok
ca
releas
reduc
ppad
ppnd
control
valu
fig
focu
identifi
novel
penetr
inhibitor
naadp
signal
arbitrari
cutoff
inhibit
control
naadpevok
ca
signal
amplitud
use
candid
priorit
red
box
fig
threshold
corral
compound
compound
caus
chang
elev
baselin
fluoresc
valu
preincub
period
also
exclud
subsequ
analysi
one
exampl
ionophor
fig
anoth
exampl
serca
inhibitor
thapsigargin
deplet
er
ca
content
abrog
naadp
respons
acid
ca
store
fig
also
exclud
known
modul
naadpevok
ca
signal
thionadp
known
contain
contamin
naadp
fig
follow
prune
top
cohort
put
inhibitor
priorit
rank
trifluoperazin
fig
analysi
known
pharmacolog
activ
screen
ligand
comparison
subset
top
eighteen
candid
inhibitor
reveal
enrich
neurotransmiss
classif
dopaminerg
modul
particular
supplementari
fig
tabl
collat
rank
candid
hit
primari
screen
subsequ
data
assay
screen
pipelin
three
compound
show
inhibit
naadpevok
ca
signal
primari
screen
fig
top
two
hit
rank
control
naadp
respons
rank
control
naadp
respons
cell
permeabl
inhibitor
sphingosin
kinas
k
nm
catalyz
format
sphingosin
sphingosin
lva
ttype
ca
v
blocker
addit
antagonist
action
trpc
channel
ca
v
secondari
valid
primari
screen
hit
perform
step
fig
top
hit
full
concentr
respons
curv
inhibit
naadpevok
ca
releas
sea
urchin
egg
homogen
perform
repres
curv
shown
fig
ic
valu
compound
collat
tabl
eighteen
priorit
candid
elicit
concentrationdepend
inhibit
naadpevok
ca
releas
valid
robust
primari
screen
ic
valu
span
low
micromolar
eg
racecadotril
ic
ten
micromolar
rang
compar
favor
data
obtain
current
use
inhibitor
naadp
evok
ca
signal
includ
ppad
ic
lower
potenc
commerci
sourc
hand
compar
recent
propos
inhibitor
naringenin
also
display
littl
inhibitori
activ
system
select
inhibit
naadp
pathway
assess
monitor
effect
candid
ip
evok
ca
signal
cadprevok
ca
signal
naadpevok
ca
signal
repres
compound
assay
shown
fig
final
effect
compound
pnaadp
bind
also
examin
one
potenti
mechan
inhibit
naadpevok
ca
respons
except
naadp
posit
control
ppad
none
compound
display
signific
inhibit
pnaadp
bind
sea
urchin
egg
homogen
fig
data
also
consist
failur
candid
displac
photoaffin
probe
naadp
receptor
bind
protein
mammalian
cell
extract
data
shown
sea
urchin
screen
activ
gener
group
eighteen
compound
merit
assess
activ
naadpevok
ca
signal
human
cell
step
fig
gener
prioriti
order
assess
inhibit
respons
number
b
result
librari
combin
compound
rank
amplitud
respons
greatest
inhibit
rank
left
potenti
rank
right
major
compound
rang
control
respons
shade
box
compound
exhibit
inhibit
naadpevok
ca
releas
priorit
red
box
select
character
tabl
c
raw
data
primari
screen
select
compound
ppad
ppnd
thapsigargin
thionadp
vehicl
control
dmso
enlarg
red
box
b
show
rank
top
eighteen
hit
prune
display
inhibit
naadpevok
ca
releas
prune
compound
thionadp
th
th
top
hit
shown
grey
e
trace
naadpevok
ca
releas
presenc
two
top
rank
candid
colour
line
microinject
naadp
singl
cell
rel
timeconsum
process
first
counterscreen
compound
deleteri
effect
cell
viabil
nonspecif
action
acid
ca
store
cell
viabil
screen
perform
use
luciferas
base
system
quantifi
cellular
atp
level
follow
incub
cell
bone
osteosarcoma
compound
none
compound
exhibit
toxic
treatment
paradigm
compar
control
sampl
supplementari
fig
next
effect
candid
drug
lysosom
number
ca
content
assess
simultan
monitor
chang
lysotrack
fluoresc
cytoplasm
ca
follow
addit
gpn
gpn
caus
lysosom
permeabil
ca
releas
concomit
loss
lysotrack
stain
intens
decreas
lysosom
ca
content
drugtreat
sampl
rel
control
assess
gpn
addit
decreas
lysotrack
signal
initi
drug
addit
lysosomotrop
regard
gener
action
drug
candid
lysosom
ca
store
distinct
activ
naadpevok
ca
releas
pathway
repres
trace
show
ratio
ff
green
red
lysotrack
fluoresc
signal
time
shown
fig
sever
candid
exampl
lack
display
effect
control
vehicl
gpn
bafilomycin
proteas
inhibitor
cocktail
impair
gpn
action
sever
candid
drug
exampl
prochlorperazin
trifluoperazin
fig
caus
rapid
decreas
lysotrack
stain
fig
bottom
decreas
mobiliz
lysosom
ca
content
gpn
addit
fig
top
effect
relat
strong
observ
correl
loss
lysotrack
stain
gpnevok
ca
transient
amplitud
fig
data
portfolio
candid
shown
fig
identifi
three
broad
group
compound
effect
lysotrack
gpn
signal
intens
cluster
neg
control
water
dmso
box
fig
ii
compound
penetr
effect
lysotrack
gpn
signal
intens
posit
control
bafilomycin
sever
phenothiazin
prochlorperazin
rank
thioridazin
rank
trifluoperazin
rank
iii
group
compound
profil
intermedi
group
decreas
fluoresc
ratio
versu
control
seven
candid
effect
gpnmobiliz
ca
ltr
stain
first
group
rank
rank
racecadotril
rank
rank
rank
pdmp
rank
salmeterol
rank
advanc
valid
remain
candid
pursu
context
studi
shade
row
tabl
effect
remain
seven
candid
amplitud
naadpevok
ca
signal
human
cell
examin
experi
perform
monitor
ca
releas
kinet
follow
microinject
naadp
singl
cell
fig
wherea
inject
buffer
alon
evok
small
stimulu
artefact
inject
naadp
evok
robust
ca
transient
peak
ff
n
inject
fig
action
naadp
examin
cell
preincub
candid
inhibitor
min
pretreat
well
compound
interest
ppadsth
posit
control
naadp
inhibitor
sea
urchin
assay
decreas
amplitud
naadpevok
ca
transient
control
valu
fig
howev
neither
naringenin
significantli
attenu
ca
signal
amplitud
follow
naadp
microinject
fig
examin
candid
inhibitor
reveal
vari
degre
inhibit
naadpevok
ca
respons
preincub
condit
effect
compound
control
valu
control
valu
racecadotril
control
valu
compound
highli
rank
sea
urchin
screen
rank
rank
racecadotril
rank
compar
well
ppad
control
valu
pdmp
rank
caus
lowest
extent
inhibit
tabl
summari
compound
primari
screen
inhibit
naadpevok
ca
releas
compound
rank
order
maximum
averag
inhibit
naadpevok
ca
releas
primari
screen
fig
hit
assess
concentrationrespons
pnaadp
bind
experi
sea
urchin
egg
homogen
fig
counterscreen
activ
perform
cell
cutoff
threshold
nonpursuit
candid
decreas
fluoresc
ratio
either
ca
releas
ltr
assay
valid
assay
repres
extent
inhibit
naadpevok
ca
releas
signal
mer
pseudoviru
transloc
remain
seven
candid
bold
compound
list
ipfm
rank
propyl
di
pfluorophenyl
methyl
ether
hydrochlorid
control
valu
nonetheless
still
consider
improv
naringenin
hand
final
companion
paper
establish
inhibit
either
naadpsensit
ca
releas
activ
impair
transloc
mer
pseudoviru
endolysosom
system
unbias
screen
approach
describ
gener
addit
panel
inhibitor
naadpevok
ca
signal
therefor
potenti
effect
compound
mer
pseudoviru
infect
assay
assess
result
mer
pseudoviru
bioassay
plot
along
ca
releas
inhibit
data
fig
visual
inspect
result
dataset
reveal
strong
correl
result
independ
assay
support
conclus
companion
paper
ligand
target
naadp
pathway
inhibit
mer
pseudoviru
transloc
highlight
new
scaffold
manipul
naadpdepend
signal
process
mammalian
cell
perform
proof
principl
unbias
screen
sea
urchin
egg
homogen
system
goal
use
system
entri
point
valid
pipelin
aim
discov
novel
chemic
scaffold
inhibit
naadpevok
ca
releas
discoveri
modul
naadpevok
ca
signal
import
appreci
grow
role
pathway
dy
regul
cellular
process
certainli
room
improv
defin
ligand
improv
select
reliabl
activ
naadp
signal
pathway
small
pilot
screen
compound
robust
term
signal
amplitud
fig
popul
spread
inhibitori
valu
fig
importantli
success
identifi
known
blocker
naadpevok
ca
releas
within
screen
inventori
exampl
compound
rank
highli
primari
screen
includ
p
naadp
bind
inhibitor
ppnd
primari
screen
rank
ppad
rank
ii
previous
identifi
ca
v
blocker
nicardipin
rank
diltiazem
rank
verapamil
rank
nifedipin
rank
ca
v
modul
found
within
top
hundr
hit
includ
rank
nitrendipin
rank
methoxyverapamil
rank
well
highli
rank
hit
rank
discuss
ca
v
blocker
would
predict
serv
tpc
pore
blocker
support
virtual
dock
analys
microinject
studi
tabl
b
averag
peak
ca
releas
presenc
drug
min
preincub
time
rel
vehicl
control
respons
ec
concentr
naadp
nm
cadpr
nm
ip
nm
c
analysi
effect
candid
specif
pnaadp
radioligand
bind
level
presenc
drug
rel
vehicl
control
pvalu
p
rel
dmso
control
priorit
candid
show
inhibit
peak
naadpevok
ca
signal
compris
eighteen
candid
seven
progress
valid
subsequ
assay
hit
proport
compound
consist
discoveri
rate
observ
screen
especi
agreeabl
given
low
execut
cost
urchin
screen
platform
prior
retic
use
system
unbias
screen
may
relat
concern
tractabl
structureact
relationship
urchin
human
pathway
differ
sensit
sea
urchin
mammalian
system
previous
note
structur
analog
naadp
impli
differ
naadp
bind
protein
specif
howev
relat
finer
structureact
relationship
within
defin
chemic
seri
rather
discoveri
new
scaffold
obvious
data
reflect
sensit
specif
invertebr
ca
releas
system
util
c
elegan
drosophila
drug
screen
model
note
opinion
advantag
high
assay
throughput
sea
urchin
system
offset
need
subsequ
valid
hit
naadpevok
respons
human
cell
even
similar
order
potenc
ultim
observ
sea
urchin
human
cell
bioassay
racecadotril
penetr
inhibitor
system
fig
tabl
identif
three
novel
hit
tabl
inhibit
ca
releas
human
cell
line
seen
tetrandrin
ident
condit
ii
reduc
mer
pseudoviru
transloc
level
observ
fangchinolin
fig
iii
lack
demonstr
action
counterscreen
provid
strong
support
execut
higher
throughput
screen
campaign
use
sea
urchin
egg
homogen
screen
larg
compound
librari
endogen
naadpevok
signal
mediat
via
tpc
within
acid
store
nativ
environ
mammalian
cell
would
much
daunt
prospect
screen
tpc
target
cell
surfac
fig
numer
compound
chemic
scaffold
shown
accumul
within
acid
ca
store
lumen
modul
eg
function
inhibitor
acid
sphingomyelinas
fiasma
act
substrat
lumin
enzym
alter
structur
andor
function
even
integr
lysosom
eg
osmot
lysi
gpn
exampl
compound
drop
pipelin
base
counterscreen
assay
known
fall
within
categori
multipl
phenothiazin
compound
rank
clemastin
rank
dilazep
rank
compound
display
higher
lipophil
averag
clogp
basic
pka
averag
pka
remain
dataset
exclud
compound
ipfm
oxybutynin
new
lysosomotrop
suspect
equat
lack
use
research
tool
even
clinic
drug
mani
approv
therapeut
show
mark
lysosomotrop
featur
may
actual
contribut
clinic
efficaci
especi
relev
novel
use
exist
clinic
agent
target
pathogen
travers
endolysosom
system
drug
accumul
acid
ca
store
would
desir
attribut
pathogen
target
activ
may
good
repurpos
potenti
purpos
inhibit
naadpevok
ca
releas
candid
like
indirect
seven
candid
advanc
pilot
screen
pipelin
deserv
scrutini
inhibit
naadp
evok
ca
signal
respons
human
cell
line
fig
condit
less
penetr
counterscreen
chang
lysosom
properti
observ
fig
three
top
rank
hit
racecadotrilhav
previous
shown
impair
naadpevok
ca
signal
none
compound
interf
specif
pnaadp
bind
impli
inhibit
fig
character
candid
inhibitor
lysosom
ca
store
cell
repres
trace
gpn
induc
ca
releas
top
lysosom
disrupt
bottom
cell
load
lysotrack
red
ltr
baselin
fluoresc
valu
record
min
addit
test
compound
fluoresc
monitor
min
addit
gpn
releas
lysosom
ca
measur
made
quantifi
gpn
evok
ca
releas
top
loss
ltr
fluoresc
follow
initi
drug
addit
bottom
assess
fluoresc
ratio
valu
region
highlight
green
peak
ff
ratio
red
bar
minim
ff
ratio
pic
proteas
inhibitor
cocktail
bafilomycin
b
correl
plot
depict
relationship
measur
gpn
induc
calcium
releas
yaxi
green
druginduc
lysosom
disrupt
xaxi
red
valu
replot
highlight
region
cluster
nonlysomotrop
compound
highlight
box
data
repres
peak
fluoresc
ratio
f
fluo
f
f
fluo
repres
fluoresc
peak
f
repres
fluoresc
time
minimum
lysotrack
fluoresc
ratio
f
ltr
f
f
ltr
repres
minimum
lysotrack
red
fluoresc
prior
gpn
addit
f
repres
fluoresc
time
compound
label
accord
rank
tabl
mechan
fig
low
voltageactiv
ttype
ca
v
blocker
antagonist
action
ca
v
trpc
channel
polypharmacolog
profil
may
extend
tpc
direct
electrophysiolog
analysi
need
confirm
observ
inhibit
naadp
action
ca
free
extracellular
media
fig
result
tpc
pore
block
abil
data
also
suggest
caution
attribut
mechanist
basi
effect
studi
ca
signal
cellperm
inhibitor
sphingosin
kinas
applic
caus
dosedepend
increas
cellular
sphingosin
level
elev
sphingosin
level
attenu
acid
ca
store
signal
evidenc
impair
respons
naadp
patient
niemannpick
type
fig
valid
naadpinhibitor
mammalian
cell
ca
trace
resolv
fluoresc
respons
naadp
microinject
nm
pipett
concentr
cell
treat
indic
drug
min
pretreat
individu
trace
shown
red
averag
respons
shown
black
b
quantif
peak
amplitud
naadpevok
ca
transient
microinject
cell
rel
control
blue
bar
follow
preincub
indic
drug
shown
red
bar
report
luciferas
level
merspseudoviru
cell
transloc
assay
cell
rel
control
h
dmso
follow
treatment
panel
drug
h
prior
exposur
merspseudoviru
h
period
merspseudoviru
cell
entri
detect
day
post
infect
measur
luciferas
activ
describ
fulli
companion
paper
pvalu
p
p
rel
dmso
control
diseas
inhibit
may
caus
sphingosinedepend
activ
impair
lysosom
ca
uptak
andor
lysosom
permeabil
action
mechan
would
result
observ
inhibit
naadpevok
ca
signal
racecadotril
acetorphan
neutral
endopeptidas
inhibitor
nep
use
therapeut
antidiarrh
agent
block
enkephalinmedi
intestin
fluid
secret
also
prodrug
rapidli
convert
thiorphan
low
nanomolar
nep
inhibitor
inhibit
neprilysin
amyloid
peptid
degrad
enzym
infus
thiorphan
mous
model
alzheim
diseas
associ
extens
lysosom
accumul
well
chang
lysosom
number
size
data
evid
lysosom
alter
seen
neurodegen
model
dysregul
naadp
action
experi
need
defin
mechanist
drug
impair
naadp
action
conclus
interrog
sea
urchin
egg
homogen
platform
provid
new
lead
inhibit
naadpdepend
process
naadpevok
ca
signal
well
mer
pseudoviru
infectivityin
human
cell
even
though
small
number
compound
profil
initi
unbias
pilot
screen
effect
highli
rank
compound
good
achiev
structureact
base
screen
around
known
tetrandrin
scaffold
see
companion
studi
data
provid
strong
support
execut
higher
throughput
screen
campaign
use
sea
urchin
egg
homogen
system
discov
new
ligand
manipul
naadp
signal
well
modul
cadpr
ip
action
none
